X
[{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"NIH\/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by AnaBios
Filters
Companies By Therapeutic Area
Details:
This award will support the execution of Investigational New Drug-enabling studies aimed at obtaining Food and Drug Administration approval for subsequent human dosing in a Phase 1 clinical study incliding ANB-504, a lead small molecule dual inhibitor of two sodium channels.
Lead Product(s):
ANB-504
Therapeutic Area: Neurology
Product Name: ANB-504
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $1.7 million
Upfront Cash: Undisclosed
Deal Type: Funding
September 30, 2021
Details:
AnaBios provided ex vivo data from human heart tissue to assess the pro-arrhythmic risk of the new NCX1.1 inhibitor, ORM-11372 (developed in Orion Pharma).
Lead Product(s):
ORM-11372
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: ORM-11372
Highest Development Status: Preclinical
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Orion Biotechnology
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 29, 2020